Company intelligence / Profile preview

Maitweier

Chicago, Illinois, United States

Ownership: Private
Development stage: Other

Overview

Meitheal Pharmaceuticals develops and markets generic injectables and branded biopharmaceutical products with a focus on affordable access. The portfolio includes small molecules, biologics/biosimilars for oncology support care, diabetes management insulins, fertility drugs, anti-infectives like CONTEPO™, and branded launches such as liraglutide injection. The company has achieved significant sales growth ($230M+), launched numerous products (>19 recent launches), maintains global manufacturing partnerships including FDA-approved facilities in Europe/India/China via its parent Nanjing King Friend.

Therapeutic areas: ImmunologyOncologyInfectious DiseasesEndocrinology
Modalities: Small moleculeBiologicBiosimilarPeptidesInsulin analogs
Industry: Biotech

Partnerships

Premier Inc.global manufacturing/R&D partners in Europe/India/China

Beyond the preview

Go deeper on Maitweier.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maitweier.

Explore the full profile